Šveice - franču - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - azilsartanum medoxomilum - comprimés - azilsartanum medoxomilum 20 mg ut azilsartanum medoxomilum kalicum 21.34 mg, mannitolum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, pro compresso, natrium 0.80 mg. - essentielle hypertonie - synthetika

Šveice - franču - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - azilsartanum medoxomilum - comprimés - azilsartanum medoxomilum 40 mg ut azilsartanum medoxomilum kalicum 42.68 mg, mannitolum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, pro compresso, natrium 1.60 mg. - essentielle hypertonie - synthetika

Šveice - franču - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - azilsartanum medoxomilum - comprimés - azilsartanum medoxomilum 80 mg ut azilsartanum medoxomilum kalicum 85.36 mg, mannitolum, acidum fumaricum, natrii hydroxidum, hydroxypropylcellulosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, pro compresso, natrium 3.20 mg. - essentielle hypertonie - synthetika

Šveice - franču - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 1 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.03570261 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 23.59 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika

Šveice - franču - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 2 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.071402 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 47.18 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika

Šveice - franču - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 3 mg ut guanfacini hydrochloridum, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.04073661 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 39.80 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, e 132, e 172 (flavum), pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika

Šveice - franču - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - guanfacinum - retardtabletten - guanfacinum 4 mg ut guanfacini hydrochloridum 4.56 mg, hypromellosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.054581 mg, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, lactosum monohydricum 53.07 mg, povidonum k 30, crospovidonum, glyceroli dibehenas, acidum fumaricum, e 132, e 172 (flavum), pro compresso. - le tdah chez les enfants et les jeunes (6-17 ans) - synthetika

Šveice - franču - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - anagrelidum - gélules - anagrelidum 0.5 mg ut anagrelidi hydrochloridum monohydricum, povidonum k 30, lactosum 65.76 mg, lactosum monohydricum 53.74 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, e 172 (nigrum), pro capsula. - traitement des essentiels thrombozythämie - synthetika

Šveice - franču - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - vedolizumabum - injektionslösung in einem fertigpen - vedolizumabum 108 mg, acidum citricum monohydricum, natrii citras dihydricus corresp. natrium 1.11 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.68 ml. - la colite ulcérative, morbus crohn - biotechnologika

Šveice - franču - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - vedolizumabum - injektionslösung in einer fertigspritze - vedolizumabum 108 mg, acidum citricum monohydricum, natrii citras dihydricus corresp. natrium 1.11 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.68 ml. - la colite ulcérative, morbus crohn - biotechnologika